Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin and finerenone in type 2 diabetes with chronic kidney disease
ChiCTR2500102004Phase 4Not yet recruiting
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of henagliflozin, finerenone in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by The First Medical Center of Chinese PLA General Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
henagliflozinfinerenone
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500102004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102004.